ATYR PHARMA INC

Wang Lingke’s latest ATYR Pharma buy signals confidence in a low‑priced, high‑risk stock—insider insight investors shouldn’t miss.

SC US (TTGP) LTD’s disciplined buying of ATYR Pharma’s shares signals long‑term confidence amid a 90% drop, offering investors insight into potential upside if the biotech hits key milestones.

ATYR Pharma insider sale reveals strategic shift: BOTHA ROELOF transfers 51,735 shares for estate planning, sparking investor scrutiny over future governance and capital strategy.

SC US (TTGP) buys 1.2 million ATYR Pharma shares, signaling strong insider confidence amid recent selling and a potential catalyst for future growth.

ATYR Pharma CEO’s recent sell‑to‑cover move shows routine RSU tax‑cover activity, revealing strong long‑term ownership yet short‑term dilution.

Insider buying frenzy at ATYR Pharma: Accel Growth Fund’s August 11 buy signals confidence amid heavy insider sell‑offs—evaluate ATYR’s valuation and next clinical milestones before you invest.

Insider buying at ATYR signals renewed confidence in its physiocrine pipeline, hinting at potential upside despite current earnings woes.

ATYR Pharma insider selling surge: GV 2019 GP, L.L.C. wipes out 3 million shares, raising confidence concerns and potential volatility for investors.

Insider buying spurs confidence in aTyr Pharma’s Phase 3 pulmonary sarcoidosis trial—discover how board bets signal future upside despite current volatility.

CEO Shukla’s recent insider buying signals confidence in aTyr’s 2026 FDA meeting and long‑term upside, while other execs manage liquidity amid high‑risk biotech volatility.